Author:
McCaleb Rachael V.,Johnson Jill T.
Reference17 articles.
1. Amgen Inc.Xgeva® (denosumab) prescribing information. Available at: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/xgeva/xgeva_pi.pdf. Accessed January 18, 2019.
2. Amgen Inc.Prolia® (denosumab) prescribing information. Available at: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/prolia/prolia_pi.pdf. Accessed January 18, 2019.
3. Pharmacologic prevention of skeletal-related events in cancer patients;Bottiglieri;Orthopedics,2010
4. The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials;Zhang;J Bone Oncol,2017
5. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials;Lipton;Eur J Cancer,2012
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献